Treatment of peripheral T cell lymphoma
US-10344087-B2 · Jul 9, 2019 · US
Treatment of peripheral T cell lymphoma
US11999784B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11999784-B2 |
| Application number | US-201916451051-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 25, 2019 |
| Priority date | Feb 14, 2013 |
| Publication date | Jun 4, 2024 |
| Grant date | Jun 4, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.
First claim
Opening claim text (preview).
We claim: 1. A method for detecting NKp46 expression in an individual having refractory celiac disease (RCD) and treating said individual comprising: a) obtaining a biological sample from the individual, said biological sample comprising RCD cells, contacting said RCD cells with an antibody that binds NKp46 polypeptide, and detecting NKp46 polypeptide expression on the surface of said cells; and b) treating individuals expressing NKp46 polypeptide on RCD cells with anti-NKp46 antibodies.
Assignees
Inventors
Classifications
of other specific parts of the body, e.g. brain · CPC title
- G01N33/5758Primary
involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title
- C07K16/28Primary
against receptors, cell surface antigens or cell surface determinants · CPC title
against the immunoglobulin superfamily · CPC title
Blood cells · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11999784B2 cover?
- The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifical…
- Who is the assignee on this patent?
- Innate Pharma
- What technology area does this patent fall under?
- Primary CPC classification G01N33/5758. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).